Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Cost-Benefit Analysis
Dexamethasone
Drug Costs
Drug Resistance, Neoplasm
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Models, Economic
Multiple Myeloma
Oligopeptides
Quality of Life
Quality-Adjusted Life Years
Recurrence
Retreatment
Treatment Outcome
United States

authors with profiles

Andrzej Jakubowiak